Adamis Pharmaceuticals (ADMP) recently reported their Q3 earnings with a slight miss on EPS and revenue. The company reported ~$5.9M in revenue, which is a 54% increase from Q3 of 2018. In addition, the company discussed pipeline progress, commercial partnership updates, manufacturing upgrades, and some insight into ZIMHI's PK data. Overall, the earnings report and earnings call were very informative and publicized some progress on all fronts. The market has been so fixated on ZIMHI's approval it appears that it has forgotten about the company's other products and revenue streams. Although ZIMHI is